CLC number: R77
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 0000-00-00
Cited: 23
Clicked: 5488
YANG Chong-qing, SUN Wen, GU Yang-shun. A clinical study of the efficacy of topical corticosteroids on dry eye[J]. Journal of Zhejiang University Science B, 2006, 7(8): 675-678.
@article{title="A clinical study of the efficacy of topical corticosteroids on dry eye",
author="YANG Chong-qing, SUN Wen, GU Yang-shun",
journal="Journal of Zhejiang University Science B",
volume="7",
number="8",
pages="675-678",
year="2006",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.2006.B0675"
}
%0 Journal Article
%T A clinical study of the efficacy of topical corticosteroids on dry eye
%A YANG Chong-qing
%A SUN Wen
%A GU Yang-shun
%J Journal of Zhejiang University SCIENCE B
%V 7
%N 8
%P 675-678
%@ 1673-1581
%D 2006
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.2006.B0675
TY - JOUR
T1 - A clinical study of the efficacy of topical corticosteroids on dry eye
A1 - YANG Chong-qing
A1 - SUN Wen
A1 - GU Yang-shun
J0 - Journal of Zhejiang University Science B
VL - 7
IS - 8
SP - 675
EP - 678
%@ 1673-1581
Y1 - 2006
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.2006.B0675
Abstract: Objective: To evaluate the effect of topical corticosteroid for treatment of moderate or severe dry eye. Methods: Sixty eyes of 30 patients with moderate or severe dry eye, who were not sensitive to artificial tears, were treated with 0.1% fluorometholone eye drops. Subjective symptom and objective tests were used to evaluate the efficacy of treatment before and after application of 0.1% fluorometholone eye drops for 1 week and 1 month. Side effects were also evaluated. Results: After 1 week of treatment, subjective symptoms were improved in all dry eye patients; objective tests were improved in all dry eye patients 1 month after treatment, and the difference was significant. Conclusion: Topical corticosteroid drops can rapidly and effectively relieve the symptoms and signs of moderate or severe dry eye.
[1] Avunduk, A.M., Avunduk, M.C., Varnell, E.D., Kaufman, H.E., 2003. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am. J. Ophthalmol., 136(4):593-602.
[2] Baudouin, C., 2001. The pathology of dry eye. Surv. Ophthalmol., 45(Suppl. 2):S211-S220.
[3] Brignole, F., Pisella, P.J., Goldschild, M., de Saint Jean, M., Goguel, A., Baudouin, C., 2000. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. Invest. Ophthalmol. Vis. Sci., 41(6):1356-1363.
[4] Caccavo, D., Pellegrino, N.M., Altamura, M., Rigon, A., Amati, L., Amoroso, A., Jirillo, A., 2002. Antimicrobial and immunoregulatory functions of lactoferrin and its potential therapeutic application. J. Endotoxin. Res., 8(6):403-417.
[5] Gao, J., Morgan, G., Tieu, D., Schwalb, T.A., Luo, J.Y., Wheeler, L.A., Stern, M.E., 2004. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjogrens syndrome-like MRL/lpr mice. Exp. Eye Res., 78(4):823-835.
[6] Johnson, M.E., Murphy, P.J., 2004. Changes in the tear film and ocular surface from dry eye syndrome. Prog. Retin. Eye Res., 23(4):449-474.
[7] Lee, H.K., Ryu, I.H., Seo, K.Y., Hong, S., Kim, H.C., Kim, E.K., 2006. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. Ophthalmology, 113(2):198-205.
[8] Mathers, W.D., 2000. Why the eye becomes dry: a cornea and lacrimal gland feedback model. CLAO J., 26(3):159-165.
[9] Nagelhout, T.J., Gamache, D.A., Roberts, L., Brady, M.T., Yanni, J.M., 2005. Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye. J. Ocul. Pharmacol. Ther., 21(2):139-148.
[10] Pflugfelder, S.C., 2004. Antiinflammatory therapy for dry eye. Am. J. Ophthalmol., 137(2):337-342.
[11] Pflugfelder, S.C., Maskin, S.L., Anderson, B., Chodosh, J., Holland, E.J., de Palva, C.S., Bartels, S.P., Micuda, T., Proskin, H.E., Vogel, R., 2004. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am. J. Ophthalmol., 138(3):444-457.
[12] Stern, M.E., Beuerman, R.W., Fox, R.I., Gao, J., Mircheff, A.K., Pflugfelder, S.C., 1998. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea, 17(6):584-589.
[13] Stern, M.E., Gao, J., Siemasko, K.F., Beuerman, R.W., Pflugfelder, S.C., 2004. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp. Eye Res., 78(3):409-416.
[14] Yen, M.T., Pflugfelder, S.C., Feuer, W.J., 2001. The effect of punctal occlusion on tear production, tear clearance, and ocular surface sensation in normal subjects. Am. J. Ophthalmol., 131(3):314-323.
[15] Zoukhri, D., 2006. Effect of inflammation on lacrimal gland function. Exp. Eye Res., 82(5):885-898.
Open peer comments: Debate/Discuss/Question/Opinion
<1>